Literature DB >> 22584572

Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.

Maria Sundvall1, Anna Korhonen, Katri Vaparanta, Julius Anckar, Kalle Halkilahti, Zaidoun Salah, Rami I Aqeilan, Jorma J Palvimo, Lea Sistonen, Klaus Elenius.   

Abstract

ErbB4 is a receptor tyrosine kinase implicated in the development and homeostasis of the heart, central nervous system, and mammary gland. Cleavable isoforms of ErbB4 release a soluble intracellular domain (ICD) that can translocate to the nucleus and function as a transcriptional coregulator. In search of regulatory mechanisms of ErbB4 ICD function, we identified PIAS3 as a novel interaction partner of ErbB4 ICD. In keeping with the small ubiquitin-like modifier (SUMO) E3 ligase function of protein inhibitor of activated STAT (PIAS) proteins, we showed that the ErbB4 ICD is modified by SUMO, and that PIAS3 stimulates the SUMOylation. Upon overexpression of PIAS3, the ErbB4 ICD generated from the full-length receptor accumulated into the nucleus in a manner that was dependent on the functional nuclear localization signal of ErbB4. In the nucleus, ErbB4 colocalized with PIAS3 and SUMO-1 in promyelocytic leukemia nuclear bodies, nuclear domains involved in regulation of transcription. Accordingly, PIAS3 overexpression had an effect on the transcriptional coregulatory activity of ErbB4, repressing its ability to coactivate transcription with Yes-associated protein. Finally, knockdown of PIAS3 with siRNA partially rescued the inhibitory effect of the ErbB4 ICD on differentiation of MDA-MB-468 breast cancer and HC11 mammary epithelial cells. Our findings illustrate that PIAS3 is a novel regulator of ErbB4 receptor tyrosine kinase, controlling its nuclear sequestration and function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584572      PMCID: PMC3391121          DOI: 10.1074/jbc.M111.335927

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Role of PML and PML-RARalpha in Mad-mediated transcriptional repression.

Authors:  M M Khan; T Nomura; H Kim; S C Kaul; R Wadhwa; T Shinagawa; E Ichikawa-Iwata; S Zhong; P P Pandolfi; S Ishii
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

2.  Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

Authors:  R Srinivasan; C E Gillett; D M Barnes; W J Gullick
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1.

Authors:  Ville Hietakangas; Johanna K Ahlskog; Annika M Jakobsson; Maria Hellesuo; Niko M Sahlberg; Carina I Holmberg; Andrey Mikhailov; Jorma J Palvimo; Lila Pirkkala; Lea Sistonen
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

4.  A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.

Authors:  V Kainulainen; M Sundvall; J A Määttä; E Santiestevan; M Klagsbrun; K Elenius
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

5.  gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase.

Authors:  C Y Ni; M P Murphy; T E Golde; G Carpenter
Journal:  Science       Date:  2001-10-25       Impact factor: 47.728

6.  Differential PIAS3 expression in human malignancy.

Authors:  Liming Wang; Sipra Banerjee
Journal:  Oncol Rep       Date:  2004-06       Impact factor: 3.906

7.  Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.

Authors:  Weiwen Long; Kay-Uwe Wagner; K C Kent Lloyd; Nadine Binart; Jonathan M Shillingford; Lothar Hennighausen; Frank E Jones
Journal:  Development       Date:  2003-09-03       Impact factor: 6.868

8.  WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus.

Authors:  Akihiko Komuro; Makoto Nagai; Nicholas E Navin; Marius Sudol
Journal:  J Biol Chem       Date:  2003-06-13       Impact factor: 5.157

9.  c-erbB-4 protein expression in human breast cancer.

Authors:  T Y Kew; J A Bell; S E Pinder; H Denley; R Srinivasan; W J Gullick; R I Nicholson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

10.  Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality.

Authors:  Hester Tidcombe; Amy Jackson-Fisher; Kathleen Mathers; David F Stern; Martin Gassmann; Jon P Golding
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-24       Impact factor: 12.779

View more
  18 in total

Review 1.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

2.  Sumoylation of SAE2 C terminus regulates SAE nuclear localization.

Authors:  Khue Truong; Terry D Lee; Baozong Li; Yuan Chen
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

3.  ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.

Authors:  Yuji Takahashi; Yoko Fukuda; Jun Yoshimura; Atsushi Toyoda; Kari Kurppa; Hiroyoko Moritoyo; Veronique V Belzil; Patrick A Dion; Koichiro Higasa; Koichiro Doi; Hiroyuki Ishiura; Jun Mitsui; Hidetoshi Date; Budrul Ahsan; Takashi Matsukawa; Yaeko Ichikawa; Takashi Moritoyo; Mayumi Ikoma; Tsukasa Hashimoto; Fumiharu Kimura; Shigeo Murayama; Osamu Onodera; Masatoyo Nishizawa; Mari Yoshida; Naoki Atsuta; Gen Sobue; Jennifer A Fifita; Kelly L Williams; Ian P Blair; Garth A Nicholson; Paloma Gonzalez-Perez; Robert H Brown; Masahiro Nomoto; Klaus Elenius; Guy A Rouleau; Asao Fujiyama; Shinichi Morishita; Jun Goto; Shoji Tsuji
Journal:  Am J Hum Genet       Date:  2013-10-10       Impact factor: 11.025

4.  The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.

Authors:  Veera K Ojala; Anna M Knittle; Peppi Kirjalainen; Johannes A M Merilahti; Maarit Kortesoja; Denis Tvorogov; Katri Vaparanta; Shujun Lin; Jürgen Kast; Arto T Pulliainen; Kari J Kurppa; Klaus Elenius
Journal:  J Biol Chem       Date:  2020-06-19       Impact factor: 5.157

Review 5.  Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  FEBS J       Date:  2015-07-04       Impact factor: 5.542

6.  Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland.

Authors:  Ilkka Paatero; Tiffany N Seagroves; Katri Vaparanta; Wen Han; Frank E Jones; Randall S Johnson; Klaus Elenius
Journal:  J Biol Chem       Date:  2014-06-25       Impact factor: 5.157

7.  STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Authors:  Uksha Saini; Adrian A Suarez; Shan Naidu; John J Wallbillich; Kristin Bixel; Ross A Wanner; Jason Bice; Raleigh D Kladney; Jenny Lester; Beth Y Karlan; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2018-01-16       Impact factor: 12.701

8.  Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice.

Authors:  Sudhakar Kalakonda; Shreeram C Nallar; Sausan Jaber; Susan K Keay; Ellen Rorke; Raghava Munivenkatappa; Daniel J Lindner; Gary M Fiskum; Dhananjaya V Kalvakolanu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

9.  SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase.

Authors:  Anna M Knittle; Maria Helkkula; Mark S Johnson; Maria Sundvall; Klaus Elenius
Journal:  J Biol Chem       Date:  2017-10-03       Impact factor: 5.157

10.  Identification of druggable cancer driver genes amplified across TCGA datasets.

Authors:  Ying Chen; Jeremy McGee; Xianming Chen; Thompson N Doman; Xueqian Gong; Youyan Zhang; Nicole Hamm; Xiwen Ma; Richard E Higgs; Shripad V Bhagwat; Sean Buchanan; Sheng-Bin Peng; Kirk A Staschke; Vipin Yadav; Yong Yue; Hosein Kouros-Mehr
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.